Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing
Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, for multiple cancer types, including 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Presented positive interim clinical data at 2023 ASCO…